Ruo‐Jing Li

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation”.

FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2234

N/A

0.739DataRank · unranked

24 citations

Kelly J. Norsworthy, Xin Wang, Jonathon Vallejo, Edwin C.Y. Chow, Ruo‐Jing Li +7 more

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4176

N/A

0DataRank · unranked

56 citations

Robert Q. Le, Alexei Ionan, Ruo‐Jing Li, Yinghong Wang, Ramadevi Gudi +16 more

Dimethyl Fumarate Protects against Lipopolysaccharide- (LPS-) Induced Sepsis through Inhibition of NF-κB Pathway in Mice

Mediators of Inflammation(2023)10.1155/2023/5133505

N/A

0DataRank · unranked

14 citations

Xingtong Wang, Mahendra Damarla, Rongju Sun, Qingli He, Ruo‐Jing Li +4 more

Clinical pharmacology considerations for first‐in‐human clinical trials for enzyme replacement therapy

Journal of Inherited Metabolic Disease(2024)10.1002/jimd.12746

N/A

0DataRank · unranked

4 citations

Jie Wang, Ruo‐Jing Li, Yuen Yi Hon, Shawna L. Weis, Yow‐Ming Wang +3 more